Shares of Chemours Co (NYSE:CC) have earned a consensus recommendation of “Buy” from the eleven ratings firms that are covering the stock, Marketbeat reports. Three research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is $58.00.

A number of research analysts have issued reports on the company. Barclays restated a “buy” rating and issued a $60.00 price objective on shares of Chemours in a research note on Wednesday, December 6th. Zacks Investment Research upgraded Chemours from a “hold” rating to a “strong-buy” rating and set a $61.00 price objective for the company in a research note on Tuesday, October 3rd. Jefferies Group upped their price objective on Chemours to $66.00 and gave the company a “buy” rating in a research note on Monday, December 4th. UBS Group upped their price objective on Chemours from $50.00 to $59.00 and gave the company a “neutral” rating in a research note on Friday, November 3rd. Finally, Goldman Sachs Group downgraded Chemours from a “buy” rating to a “neutral” rating and set a $55.00 price target for the company. in a research note on Wednesday, December 6th.

In other Chemours news, insider Christian W. Siemer sold 15,088 shares of the firm’s stock in a transaction dated Wednesday, December 13th. The stock was sold at an average price of $47.37, for a total value of $714,718.56. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider E Bryan Snell sold 11,878 shares of the firm’s stock in a transaction dated Monday, November 6th. The stock was sold at an average price of $53.25, for a total value of $632,503.50. Following the completion of the transaction, the insider now owns 63,063 shares of the company’s stock, valued at approximately $3,358,104.75. The disclosure for this sale can be found here. 1.14% of the stock is currently owned by corporate insiders.

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Cypress Capital Management LLC boosted its stake in Chemours by 0.5% in the 2nd quarter. Cypress Capital Management LLC now owns 31,393 shares of the specialty chemicals company’s stock worth $1,190,000 after purchasing an additional 155 shares during the period. Zacks Investment Management boosted its stake in Chemours by 1.6% in the 2nd quarter. Zacks Investment Management now owns 62,894 shares of the specialty chemicals company’s stock worth $2,385,000 after purchasing an additional 973 shares during the period. Mutual of America Capital Management LLC boosted its stake in Chemours by 0.7% in the 3rd quarter. Mutual of America Capital Management LLC now owns 151,298 shares of the specialty chemicals company’s stock worth $7,657,000 after purchasing an additional 1,036 shares during the period. Smith Asset Management Group LP boosted its stake in Chemours by 3.1% in the 3rd quarter. Smith Asset Management Group LP now owns 44,489 shares of the specialty chemicals company’s stock worth $2,252,000 after purchasing an additional 1,333 shares during the period. Finally, Scotia Capital Inc. boosted its stake in Chemours by 21.0% in the 2nd quarter. Scotia Capital Inc. now owns 8,631 shares of the specialty chemicals company’s stock worth $328,000 after purchasing an additional 1,500 shares during the period. Institutional investors and hedge funds own 74.36% of the company’s stock.

Shares of Chemours (NYSE:CC) traded up $2.42 during trading hours on Friday, reaching $54.02. The company’s stock had a trading volume of 1,626,829 shares, compared to its average volume of 1,920,000. The company has a market cap of $9,980.00 and a P/E ratio of 37.26. The company has a debt-to-equity ratio of 5.07, a current ratio of 2.19 and a quick ratio of 1.63. Chemours has a 52-week low of $24.17 and a 52-week high of $58.08.

Chemours (NYSE:CC) last announced its quarterly earnings data on Thursday, November 2nd. The specialty chemicals company reported $1.12 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.01 by $0.11. The firm had revenue of $1.58 billion during the quarter, compared to the consensus estimate of $1.59 billion. Chemours had a return on equity of 116.80% and a net margin of 4.86%. The business’s revenue for the quarter was up 13.3% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.61 EPS. sell-side analysts forecast that Chemours will post 3.65 EPS for the current year.

The company also recently declared a quarterly dividend, which will be paid on Thursday, March 15th. Stockholders of record on Thursday, February 15th will be paid a dividend of $0.17 per share. This is an increase from Chemours’s previous quarterly dividend of $0.03. The ex-dividend date of this dividend is Wednesday, February 14th. This represents a $0.68 annualized dividend and a dividend yield of 1.26%. Chemours’s dividend payout ratio is presently 8.28%.

Chemours declared that its board has authorized a stock repurchase program on Friday, December 1st that permits the company to buyback $500.00 million in shares. This buyback authorization permits the specialty chemicals company to reacquire shares of its stock through open market purchases. Stock buyback programs are generally a sign that the company’s board believes its shares are undervalued.

WARNING: This report was published by Watch List News and is owned by of Watch List News. If you are reading this report on another domain, it was illegally copied and reposted in violation of U.S. and international copyright and trademark law. The legal version of this report can be read at https://www.watchlistnews.com/chemours-co-cc-receives-consensus-rating-of-buy-from-brokerages/1815792.html.

About Chemours

The Chemours Company is a provider of performance chemicals. The Company operates through three segments: Titanium Technologies, Fluoroproducts and Chemical Solutions. The Titanium Technologies segment is a producer of titanium dioxide (TiO2). The Fluoroproducts segment is a provider of fluoroproducts, including refrigerants and industrial fluoropolymer resins.

Analyst Recommendations for Chemours (NYSE:CC)

Receive News & Ratings for Chemours Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemours and related companies with MarketBeat.com's FREE daily email newsletter.